title: Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia.
abstract: We assessed qualitative and quantitative differences in surfactant lipid composition of bronchoalveolar lavage (BAL) fluid in patients with acquired immune deficiency syndrome (AIDS) and Pneumocystis carinii (PC) pneumonia. Five normal volunteers and 27 patients with human immunodeficiency virus (HIV) infection underwent BAL for evaluation of possible pulmonary infection. Bronchoalveolar lavage studies in eight patients were negative for PC organisms, and 19 were positive. Pneumocystis carinii pneumonia was graded (mild vs moderate to severe) by initial alveolar-arterial oxygen gradient. Bronchoalveolar lavage fluid was centrifuged, the lipids were extracted from the supernatant, and total lipid profiles of dephosphorylated glycerolipids were analyzed as trimethylsilylether derivatives by high temperature gas-liquid chromatography. Phospholipase A2 levels were determined using a radiolabeled E coli membrane method. Compared to the normal volunteers (109 +/- 13 micrograms/5 ml) and the PC negative group (107 +/- 13 micrograms/5 ml), total BAL lipid was reduced for both the mild PC pneumonia group (73 +/- 10 micrograms/5 ml) and the moderate to severe PC pneumonia group (46 +/- 4 micrograms/5 ml). There was a parallel reduction of diacylglycerol lipids: normal volunteers, 52 +/- 7 micrograms/5 ml; PC negative, 52 +/- 9 micrograms/5 ml; mild PC pneumonia, 35 +/- 7 micrograms/5 ml; and moderate to severe PC pneumonia, 15 +/- 2 micrograms/5 ml. Phospholipase A2 activity in moderate to severe PC pneumonia was twice that of the PC negative patients, and 30 times that for normals. The data demonstrate a marked diminution in surfactant glycerophospholipid in patients with AIDS and PC pneumonia and suggest a potential role for surfactant abnormality in the pathophysiology of this disease.
authors.affiliation: Critical Care Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda 20892.
authors.forename: A G
authors.initials: AG
authors.lastname: Hoffman
authors.forename: M G
authors.initials: MG
authors.lastname: Lawrence
authors.forename: F P
authors.initials: FP
authors.lastname: Ognibene
authors.forename: A F
authors.initials: AF
authors.lastname: Suffredini
authors.forename: G Y
authors.initials: GY
authors.lastname: Lipschik
authors.forename: J A
authors.initials: JA
authors.lastname: Kovacs
authors.forename: H
authors.initials: H
authors.lastname: Masur
authors.forename: J H
authors.initials: JH
authors.lastname: Shelhamer
mesh_terms: D000328:Adult; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D001999:Bronchoscopy; D004075:Diglycerides / Q000032:analysis; D005230:Fatty Acids, Nonesterified / Q000032:analysis; D005989:Glycerides / Q000032:analysis; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D008055:Lipids / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000032:analysis; D010741:Phospholipases A / Q000032:analysis*; D054467:Phospholipases A2; D010743:Phospholipids / Q000032:analysis; D011020:Pneumonia, Pneumocystis / Q000378:metabolism*; D011663:Pulmonary Surfactants / Q000737:chemistry*
chemical_list: D004075:Diglycerides; D005230:Fatty Acids, Nonesterified; D005989:Glycerides; D008055:Lipids; D010713:Phosphatidylcholines; D010743:Phospholipids; D011663:Pulmonary Surfactants; D010741:Phospholipases A; D054467:Phospholipases A2